A metabolomic analysis of omega-3 fatty acid-mediated attenuation of western diet-induced nonalcoholic steatohepatitis in LDLR-/- mice

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Depner, Christopher M ^a,b   Traber, Maret G ^a,b   Bobe, Gerd ^a,b   Kensicki, Elizabeth ^c   Bohren, Kurt M ^d   Milne, Ginger ^e   Jump, Donald B ^a,b  

^a OREGON STATE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c METABOLON INC   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 17,18 DIHYDROXYEICOSATETRAENOIC ACID; 18 HYDROXYEICOSAPENTAENOIC ACID; ALPHA TOCOPHEROL; ASCORBIC ACID; CHOLESTEROL; CITRIC ACID; F2 ISOPROSTANE DERIVATIVE; F3 ISOPROSTANE DERIVATIVE; GLUTATHIONE; GLYCEROPHOSPHOLIPID; ISOPROSTANE DERIVATIVE; LACTOYLGLUTATHIONE; LACTOYLGLUTATHIONE LYASE; METHYLGLYOXAL; MITOGUAZONE; MONOUNSATURATED FATTY ACID; OLIVE OIL; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PALMITOYLSPHINGOMYELIN; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID; SPHINGOLIPID; SPHINGOMYELIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; FAT INTAKE; GENE EXPRESSION; HISTOPATHOLOGY; LDLR GENE; LIPID COMPOSITION; LIPID METABOLISM; LIPOGENESIS; MALE; MARKER GENE; METABOLITE; METABOLOMICS; MOUSE; NASH GENE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; THERAPY EFFECT;

ANIMALS; CARBON; DIET; DISEASE MODELS, ANIMAL; ENDOTOXINS; ENERGY METABOLISM; FATTY ACIDS; FATTY ACIDS, MONOUNSATURATED; FATTY ACIDS, OMEGA-3; FATTY LIVER; LIPID PEROXIDATION; LIVER; MALE; METABOLOME; METABOLOMICS; MICE; MICE, KNOCKOUT; OXIDATIVE STRESS; PHOSPHOLIPIDS; RECEPTORS, LDL; SPHINGOMYELINS;

EID: 84892930540     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083756     Document Type: Article

References (47)

1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142: 1592-1609.
2. McCullough AJ (2006) Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 40 Suppl 1: S17-S29. PubMed: 16540762.
3. Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34: 274-285. doi:10.1111/j.1365-2036.2011.04724.x. PubMed: 21623852.
4. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK et al. (2011) Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141: 1249-1253. doi:10.1053/j.gastro. 2011.06.061. PubMed: 21726509.
5. Day CP, James OF (1998) Steatohepatitis: a tale of two "hits"? Gastroenterology 114: 842-845. doi:10.1016/S0016-5085(98)70599-2. PubMed: 9547102.
6. Lam BP, Younossi ZM (2009) Treatment regimens for non-alcoholic fatty liver disease. Ann Hepatol 8 Suppl 1: S51-S59. PubMed: 19381125.
7. Musso G, Gambino R, Cassader M (2010) Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 11: 430-445. PubMed: 19845871.
8. Depner CM, Philbrick KA, Jump DB (2013) Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr(-/-) mouse model of western diet-induced nonalcoholic steatohepatitis. J Nutr 143: 315-323. doi: 10.3945/jn.112.171322. PubMed: 23303872.
9. de Wit NJ, Afman LA, Mensink M, Müller M (2012) Phenotyping the effect of diet on non-alcoholic fatty liver disease. J Hepatol 57: 1370-1373. doi:10.1016/j.jhep.2012.07.003. PubMed: 22796155.
10. Martel C, Esposti DD, Bouchet A, Brenner C, Lemoine A (2012) Non-alcoholic steatohepatitis: new insights from OMICS studies. Curr Pharm Biotechnol 13: 726-735. doi:10.2174/138920112799857558. PubMed: 22122481.
11. Kalhan SC, Guo L, Edmison J, Dasarathy S, McCullough AJ et al. (2011) Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 60: 404-413. doi:10.1016/j.metabol.2010.03.006. PubMed: 20423748.
12. Barr J, Vázquez-Chantada M, Alonso C, Pérez-Cormenzana M, Mayo R et al. (2010) Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J Proteome Res 9: 4501-4512. doi:10.1021/pr1002593. PubMed: 20684516.
13. Kalish BT, Le HD, Gura KM, Bistrian BR, Puder M (2013) A metabolomic analysis of two intravenous lipid emulsions in a murine model. PLOS ONE 8: e59653. doi:10.1371/journal.pone.0059653. PubMed: 23565157.
14. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J et al. (2007) A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46: 1081-1090. doi:10.1002/hep.21763. PubMed: 17654743.
15. Garcia-Heredia A, Kensicki E, Mohney RP, Rull A, Triguero I et al. (2013) Paraoxonase-1 Deficiency Is Associated with Severe Liver Steatosis in Mice Fed a High-fat High-cholesterol Diet: A Metabolomic. Approach - J Proteome Res (In press).
16. Wei Y, Wang D, Moran G, Estrada A, Pagliassotti MJ (2013) Fructose-induced stress signaling in the liver involves methylglyoxal. Nutr. Meta (Lond) 10: 32-38. doi:10.1186/1743-7075-10-32.
17. -/- mice. J Nutr 142: 1495-1503. doi:10.3945/jn.112.158865. PubMed: 22739374.
18. Saraswathi V, Gao L, Morrow JD, Chait A, Niswender KD et al. (2007) Fish oil increases cholesterol storage in white adipose tissue with concomitant decreases in inflammation, hepatic steatosis, and atherosclerosis in mice. J Nutr 137: 1776-1782. PubMed: 17585030.
19. Milne GL, Yin H, Morrow JD (2008) Human biochemistry of the isoprostane pathway. J Biol Chem 283: 15533-15537. doi:10.1074/jbc.R700047200. PubMed: 18285331.
20. Tripathy S, Torres-Gonzalez M, Jump DB (2010) Elevated hepatic fatty acid elongase-5 activity corrects dietary fat-induced hyperglycemia in obese C57BL/6J mice. J Lipid Res 51: 2642-2654. doi:10.1194/jlr.M006080. PubMed: 20488798.
21. Kim HY, Salem N Jr. (1990) Separation of lipid classes by solid phase extraction. J Lipid Res 31: 2285-2289. PubMed: 2090722.
22. Pawar A, Jump DB (2003) Unsaturated fatty acid regulation of peroxisome proliferator-activated receptor alpha activity in rat primary hepatocytes. J Biol Chem 278: 35931-35939. doi:10.1074/jbc.M306238200. PubMed: 12853447.
23. Thornalley PJ (1996) Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification - a role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol 27: 565-573. doi: 10.1016/0306-3623(95)02054-3. PubMed: 8853285.
24. Walenbergh SMA, Koek GH, Bieghs V, Shiri-Sverdlov R (2013) Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins. J Hepatol 58: 801-820. doi:10.1016/j.jhep.2012.11.014. PubMed: 23183522.
25. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C et al. (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56: 1761-1772. doi:10.2337/db06-1491. PubMed: 17456850.
26. Harte AL, da Silva NF, Creely SJ, McGee KC, Billyard T et al. (2010) Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond) 7: 15. doi:10.1186/1476-9255-7-15. PubMed: 20353583.
27. Tilg H, Moschen AR (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52: 1836-1846. doi:10.1002/hep.24001. PubMed: 21038418.
28. Marra F, Gastaldelli A, Baroni GS, Tell G, Tiribelli C (2008) Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 14: 72-81. doi:10.1016/j.molmed.2007.12.003. PubMed: 18218340.
29. Erridge C, Attina T, Spickett CM, Webb DJ (2007) A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 86: 1286-1292. PubMed: 17991637.
30. Laugerette F, Vors C, Géloën A, Chauvin MA, Soulage C et al. (2011) Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation. J Nutr Biochem 22: 53-59. doi: 10.1016/j.jnutbio.2009.11.011. PubMed: 20303729.
31. Fessler MB, Parks JS (2011) Intracellular lipid flux and membrane microdomains as organizing principles in inflammatory cell signaling. J Immunol 187: 1529-1535. doi:10.4049/jimmunol.1100253. PubMed: 21810617.
32. Bikman BT, Summers SA (2011) Sphingolipids and hepatic steatosis. Adv Exp Med Biol 721: 87-97. doi:10.1007/978-1-4614-0650-1-6. PubMed: 21910084.
33. Jump DB, Tripathy S, Depner CM (2013) Fatty Acid-regulated transcription factors in the liver. Annu Rev Nutr 33: 249-269. doi: 10.1146/annurev-nutr- 071812-161139. PubMed: 23528177.
34. Dobrzyn A, Dobrzyn P, Lee SH, Miyazaki M, Cohen P et al. (2005) Stearoyl-CoA desaturase-1 deficiency reduces ceramide synthesis by downregulating serine palmitoyltransferase and increasing beta-oxidation in skeletal muscle. Am J Physiol Endocrinol Metab 288: E599-E607. PubMed: 15562249.
35. Botolin D, Wang Y, Christian B, Jump DB (2006) Docosahexaneoic acid (22:6,n-3) regulates rat hepatocyte SREBP-1 nuclear abundance by Erk- and 26S proteasome-dependent pathways. J Lipid Res 47: 181-192. PubMed: 16222032.
36. Weylandt KH, Chiu CY, Gomolka B, Waechter SF, Wiedenmann B (2012) Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvin and protectin formation. Prostaglandins Other Lipid Mediat 97: 73-82. doi:10.1016/j.prostaglandins.2012.01.005. PubMed: 22326554.
37. Wei Y, Wang D, Moran G, Estrada A, Pagliassotti MJ (2013) Fructose-induced stress signaling in the liver involves methylglyoxal. Nutr Metab (Lond) 10: 32. doi:10.1186/1743-7075-10-32. PubMed: 23566306.
38. Szabo G, Csak T (2012) Inflammasomes in liver diseases. J Hepatol 57: 642-654. doi:10.1016/j.jhep.2012.03.035. PubMed: 22634126.
39. Simons K, Ikonen E (1997) Functional rafts in cell membranes. Nature 387: 569-572. doi:10.1038/42408. PubMed: 9177342.
40. Wassall SR, Stillwell W (2008) Docosahexaenoic acid domains: the ultimate non-raft membrane domain. Chem Phys Lipids 153: 57-63. doi:10.1016/j. chemphyslip.2008.02.010. PubMed: 18343224.
41. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF et al. (2011) Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305: 1659-1668. doi:10.1001/jama.2011.520. PubMed: 21521847.
42. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM et al. (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362: 1675-1685. doi:10.1056/NEJMoa0907929. PubMed: 20427778.
43. Buettner GR (1993) The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch Biochem Biophys 300: 535-543. doi:10.1006/abbi.1993.1074. PubMed: 8434935.
44. Traber MG (2007) Vitamin E regulatory mechanisms. Annu Rev Nutr 27: 347-362. doi:10.1146/annurev.nutr.27.061406.093819. PubMed: 17439363.
45. Arnold C, Markovic M, Blossey K, Wallukat G, Fischer R et al. (2010) Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of omega-3 fatty acids. J Biol Chem 285: 32720-32733. doi:10.1074/jbc.M110.118406. PubMed: 20732876.
46. Ikeda R, Ishii K, Hoshikawa Y, Azumi J, Arakaki Y et al. (2011) Reactive oxygen species and NADPH oxidase 4 induced by transforming growth factor beta1 are the therapeutic targets of polyenylphosphatidylcholine in the suppression of human hepatic stellate cell activation. Inflamm Res 60: 597-604. doi:10.1007/s00011-011-0309-6. PubMed: 21318733.
47. Nobili V, Bedogni G, Alisi A, Pietrobattista A, Risé P et al. (2011) Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child 96: 350-353. doi:10.1136/adc.2010. 192401. PubMed: 21233083.